GarryHSchwartzMD

PubMed

• 7 citations
  A case study of 10 patients administered HBOC-201 in high doses over a prolonged period: outcomes during severe anemia when transfusion is not an option.
  Marc Zumberg, Jed B. Gorlin, Elizabeth A. Griffiths, Garry Schwartz, Bradley S. Fletcher, Katherine Walsh, Kim Hien T. Dao, Amanda M. VanSandt, Mauricio Lynn, Aryeh Sh...> ;Transfusion. 2020 May 1
• 19 citations
  Use of the blood substitute HBOC‐201 in critically ill patients during sickle crisis: a three‐case series
  Jonathan M. Davis, Nura El-Haj, Nimish Shah, Garry Schwartz, Margaret Block, James Wall, Mark Tidswell, Ernest DiNino> ;Transfusion. 2018 Jan 1
• 37 citations
  Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity
  Daniel L. Hertz, Allison M. Deal, Joseph G. Ibrahim, Christine M. Walko, Karen E. Weck, Steven M. Anderson, Gustav Magrinat, Oludamilola Olajide, Susan E. Moore, Rache...> ;The Oncologist. 2016 Jul 1
• 39 citations
  In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles
  Daniel L. Hertz, Anna C. Snavely, Howard L. McLeod, Christine M. Walko, Joseph G. Ibrahim, Steven M. Anderson, Karen E. Weck, Gustav Magrinat, Oludamilola Olajide, Sus...> ;British Journal of Clinical Pharmacology. 2015 Nov 1
• 5 citations
  Patients' Understanding of How Genotype Variation Affects Benefits of Tamoxifen Therapy for Breast Cancer
  Noel T. Brewer, Jessica T. DeFrank, Wing Keung Chiu, Joseph G. Ibrahim, Christine M. Walko, Peter Rubin, Oludamilola Olajide, Susan G. Moore, Rachael E. Raab, Daniel R...> ;Public Health Genomics. 2014 Jan 1
• 62 citations
  Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non–Small-Cell Lung Cancer: Results of a Phase I/II Trial
  Mark A. Socinski, Thomas E. Stinchcombe, Dominic T. Moore, Scott N. Gettinger, Roy H. Decker, W. Jeffrey Petty, A. William Blackstock, Garry Schwartz, Scott P. Lankfor...> ;Journal of Clinical Oncology. 2012 Oct 8
• 36 citations
  Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.
  Alain C. Mita, Kyriakos P. Papadopoulos, M.J.A. de Jonge, Garry Schwartz, Jaap Verweij, Monica M. Mita, A. Ricart, Q S-C Chu, Anthony W. Tolcher, Leslie Wood, S McCart...> ;British Journal of Cancer. 2011 Sep 27
• 32 citations
  A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV No...
  Thomas E. Stinchcombe, Amy H. Peterman, Carrie B. Lee, Dominic T. Moore, Jennifer L. Beaumont, Daniel S. Bradford, Kamal Bakri, Mark Taylor, Jeffrey M. Crane, Garry Sc...> ;Journal of Thoracic Oncology. 2011 Sep 1
• 22 citations
  Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies
  Bahram Forouzesh, Manuel Hidalgo, Quincy Siu-Chung Chu, Alain C. Mita, Monica M. Mita, Garry Schwartz, José Enrique Garzón Jimeno, J. Gomez, Vicente Alfaro, C. Lebedin...> ;Clinical Cancer Research. 2009 May 15
• 122 citations
  Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study
  A. Ricart, Anthony W. Tolcher, Glenn Liu, Kyle D. Holen, Garry Schwartz, Mark R. Albertini, Geoffrey R. Weiss, Salim Yazji, Chee Ng, George Wilding> ;Clinical Cancer Research. 2008 Dec 1
• 45 citations
  Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies
  Quincy Chu, Garry Schwartz, Johann S. de Bono, Deborah A. Smith, Kevin M. Koch, M. J. Versola, Lini Pandite, Nikita Arya, Jan Curtright, Ronald A. Fleming, Peter T.C. ...> ;Journal of Clinical Oncology. 2007 Aug 20
• 43 citations
  A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas
  Quincy Chu, Bahram Forouzesh, Samira Syed, Monica Mita, Garry Schwartz, Joshua Cooper, Janet Curtright, Eric K. Rowinsky> ;Investigational New Drugs. 2007 Jan 20
• 10 citations
  A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies
  Eric K. Rowinsky, Muralidhar Beeram, Lisa A. Hammond, Garry Schwartz, Johann S. de Bono, Baharam Forouzesh, Quincy Chu, Jane E. Latz, Shengyan Hong, William J. John, B...> ;Clinical Cancer Research. 2007 Jan 15
• 22 citations
  Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors
  Amita Patnaik, Debra L. Wood, Anthony W. Tolcher, Marta Hamilton, Jeffrey I. Kreisberg, Lisa A. Hammond, Garry Schwartz, Muralidhar Beeram, Manuel Hidalgo, Monica M. M...> ;Clinical Cancer Research. 2006 Dec 15
• 34 citations
  A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense™, G3139) and irinotecan in patients with metastatic colorectal cancer
  Monica M. Mita, Leonel Ochoa, Eric K. Rowinsky, John G. Kuhn, Garry Schwartz, Lisa A. Hammond, Amita Patnaik, I. T. Yeh, Elzbieta Izbicka, K. Berg, Anthony W. Tolcher> ;Annals of Oncology. 2006 Feb 1
• 116 citations
  A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer
  Anthony W. Tolcher, Kim N. Chi, John G. Kuhn, Martin E. Gleave, Amita Patnaik, Chris H. Takimoto, Garry Schwartz, Ian M. Thompson, K. Berg, Susan D’Aloisio, Nevin Murr...> ;Clinical Cancer Research. 2005 May 15
• 1 citations
  A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
  Garry Schwartz, Christopher B. Jones, Mitchell Garrison, Amita Patnaik, Chris H. Takimoto, Heather McCreery, Michael Skinner, Anthony W. Tolcher, Eric K. Rowinsky> ;Investigational New Drugs. 2004 Nov 1
• 45 citations
  A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
  Samira Syed, Chris H. Takimoto, Manuel Hidalgo, Jinee Rizzo, John G. Kuhn, Lisa A. Hammond, Garry Schwartz, Anthony W. Tolcher, Amita Patnaik, S. Gail Eckhardt, Eric K...> ;Clinical Cancer Research. 2004 Oct 1
• 54 citations
  A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in...
  Anthony W. Tolcher, John G. Kuhn, Garry Schwartz, Amita Patnaik, Lisa A. Hammond, Ian M. Thompson, Howard Fingert, David Bushnell, Shazli N. Malik, Jeffrey I. Kreisber...> ;Clinical Cancer Research. 2004 Aug 1
• 41 citations
  Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies
  Quincy Siu-Chung Chu, Lisa A. Hammond, Garry Schwartz, Leonel Ochoa, Sun Young Rha, Louis Denis, Kathleen Molpus, Brian Roedig, Stephen P. Letrent, Bharat Damle, Arthu...> ;Clinical Cancer Research. 2004 Aug 1
• 240 citations
  Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer
  Eric K. Rowinsky, Garry Schwartz, Jared A. Gollob, John A. Thompson, Nicholas J. Vogelzang, Robert A. Figlin, Ronald M. Bukowski, Naomi B. Haas, Pamela Lockbaum, Yu Pi...> ;Journal of Clinical Oncology. 2004 Aug 1
• A pharmacokinetic (PK) dose escalation study of DX-8951f (DX) in adult cancer patients with hepatic dysfunction: A comparison of the NCI hepatic dysfunction criteria a...
  Takimoto CH, Saif MW, Lorusso PM, Sweeney C, Ducharme MP, Chu SQ, Schwartz GH, Danna M, De Jager RL, Rowinsky EK> ;J. Clin. Oncol.. 2004-07-15
• 169 citations
  Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
  Kenneth A. Foon, Xiao Dong Yang, Louis M. Weiner, Arie S. Belldegrun, Robert A. Figlin, Jeffrey Crawford, Eric K. Rowinsky, Janice P. Dutcher, Nicholas J. Vogelzang, J...> ;International Journal of Radiation Oncology, Biology, Physics. 2004 Mar 1
• 12 citations
  A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies
  Bahram Forouzesh, Chris H. Takimoto, Andrew Goetz, Sami Diab, Lisa A. Hammond, Leslie Smetzer, Garry Schwartz, Robert J. Gazak, John T. Callaghan, Daniel D. Von Hoff, ...> ;Clinical Cancer Research. 2003 Nov 15
• 26 citations
  A Phase I, Pharmacokinetic, and Biological Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Gemcitabine in Patients with Advanced Malignancies
  Amita Patnaik, S. Gail Eckhardt, Elzbieta Izbicka, Anthony A. Tolcher, Lisa A. Hammond, Chris H. Takimoto, Garry Schwartz, Heather McCreery, Andrew Goetz, Masataka Mor...> ;Clinical Cancer Research. 2003 Oct 15
• Join now to see all